Abstract
The oral anticoagulation efficacy of dabigatran has been proven superior to that of warfarin in the prevention of stroke and systemic embolism, with similar risks of bleeding. However, the lack of a specific antidote for dabigatran has led to persistent concerns of bleeding risk in patients undergoing invasive procedures. This multi-center, multi-national study retrospectively compared rates of bleeding and thrombotic complications in 4591 patients receiving either dabigatran or warfarin therapy who underwent surgery or other invasive procedures including dental work, cardiac catheterization, and invasive diagnostic procedures over a 2-year period.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
